MetaCap

Alumis (ALMS) vs Zevra Therapeutics (ZVRA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Zevra Therapeutics (ZVRA) has outperformed Alumis (ALMS) over the past year, gaining 1.9% versus a loss of 45.8%. Zevra Therapeutics is the larger company by market cap ($521.3 million vs $514.1 million), about 1.0 times the size. Zevra Therapeutics converts more of its revenue into profit, with a net margin of 78.2% versus -1011.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALMS-45.75%ZVRA+1.86%
+333%+135%-64%
Nov 21, 20251 yearNov 20, 2026
ALMS-70.23%ZVRA+78.78%
+198%+53%-92%
Jun 24, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALMS versus ZVRA key metrics
MetricALMSZVRA
Share price$3.96$8.76
Market cap$514.09M$521.26M
1-day change-8.55%-3.42%
YTD return-59.43%-2.23%
1-year return-45.75%+1.86%
5-year return—+8.82%
P/E ratio (TTM)—7.18
Forward P/E—9.84
EPS (TTM)$-3.53$1.22
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$24.05M$106.47M
Revenue growth (YoY)—+350.91%
Net income (latest FY)$-243.32M$83.23M
Gross margin—84.52%
Operating margin-1886.92%-59.12%
Net margin-1011.75%78.17%
52-week high$31.35$15.04
52-week low$3.94$8.01
Distance from 52-week high-87.37%-41.74%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+540.91%+162.56%
Average volume2.87M954.53K
Shares outstanding129.82M59.50M
Employees25161
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ZVRA has outperformed ALMS by 47.6 percentage points over the past year.
  • Zevra Therapeutics is more profitable, keeping 78.2 cents of every revenue dollar as net income versus -1011.7 cents for Alumis.

About Alumis

ALMS stock →

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 251 employees

About Zevra Therapeutics

ZVRA stock →

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 61 employees

ALMS vs ZVRA FAQ

Which is bigger, Alumis or Zevra Therapeutics?

Zevra Therapeutics (ZVRA) is larger, with a market capitalization of $521.26M compared with $514.09M for Alumis (ALMS).

Which stock has performed better over the past year, ALMS or ZVRA?

ZVRA returned +1.86% over the past 12 months, compared with -45.75% for ALMS (price return, excluding dividends). Past performance does not predict future results.

Are Alumis and Zevra Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons